Together, these results clearly established the significance of epigenetic regulator acetyltransferase p300 as a potential target of epidrug development for amelioration of hypertension-induced pathological cardiac hypertrophy and myocardial fibrosis, the leading cause of heart-failure-related deaths. The gene discussed is EP300; the disease is cardiac hypertrophy.